Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

36.72 +0.43 (+1.18%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Cramer Backs This Mining Giant After $1.6B Bet
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth. 
Via Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors. 
Via Chartmill
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook
Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors. 
Via Stocktwits
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025. 
Via Benzinga
Why TG Therapeutics Stock Was Tumbling Today
Via The Motley Fool
Earnings Scheduled For May 5, 2025
Via Benzinga
Why TG Therapeutics Stock Was Soaring This Week
Via The Motley Fool
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts
Via Benzinga
TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
Via Benzinga
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million. 
Via Stocktwits
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate 
Via Chartmill
Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX).
UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX). 
Via Chartmill
A Closer Look at TG Therapeutics's Options Market Dynamics
Via Benzinga
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank.
NASDAQ:TGTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
Price Over Earnings Overview: TG Therapeutics
Via Benzinga
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX). 
Via Chartmill
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
The companies both have drugs that treat relapsing forms of multiple sclerosis. 
Via Investor's Business Daily
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher. 
Via Benzinga
How does TG THERAPEUTICS INC (NASDAQ:TGTX) stack up against Mark Minervini’s strategy?
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued.
Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?
Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength. 
Via Benzinga
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year. 
Via Stocktwits
Stocks Pivot Lower On Trade Fears, Manufacturing Data
Despite earlier indicating a strong start to March, stocks are lower this afternoon amid trade war concerns. 
Via Talk Markets
Topics Stocks / Equities World Trade
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide
The company has gained notoriety for its multiple sclerosis treatment. 
Via Investor's Business Daily
Topics Earnings
Earnings Scheduled For March 3, 2025
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With TG Therapeutics Stock Tuesday?
TG Therapeutics Inc (NASDAQ:TGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.